• MJHLS Brand Logo

© 2025 MJH Life Sciences™ and The Center for Biosimilars - Biosimilars, Health Economics & Insights. All rights reserved.

Patients With nAMD Maintain Vision on Aflibercept Biosimilar ABP 938

September 03, 2025

A new biosimilar for aflibercept shows similar efficacy and safety in treating neovascular age-related macular degeneration (nAMD), enhancing patient access to treatment.

Biosimilars News Roundup: August 2025

September 02, 2025

FDA Greenlights Fifth Pair of Denosumab Biosimilars: Bildyos and Bilprevda

September 02, 2025

The Top 5 Biosimilar Articles for the Week of August 25

August 29, 2025

Alvotech Reports Record-Breaking First Half of 2025 Amid Strong Biosimilar Sales

August 27, 2025

Senators Introduce Bipartisan Legislation to Protect Skinny Labeling

January 2nd 2025

By Skylar Jeremias

Article

To close out the year, 4 senators came together to introduce a new bipartisan bill to protect biosimilar and generic drug manufacturers from patent litigation when obtaining “skinny label” approvals for their products.

Cetuximab Biosimilar Receives NMPA Approval for RAS/BRAF Wild-Type CRC

January 1st 2025

By Courtney Flaherty

Article

First-line cetuximab beta injection has received NMPA marketing approval in RAS/BRAF wild-type metastatic colorectal cancer.

The Top 5 Most-Read Biosimilar Articles of 2024

December 31st 2024

By Skylar Jeremias

Article

The top 5 biosimilar-related articles of the year highlight a significant shift in the pharmaceutical industry, with projections indicating strong uptake in biosimilars at the expense of the originator products, despite challenges like uptake disparities and safety concerns.

The Top 5 Most-Read Ophthalmology Articles of 2024

December 30th 2024

By Skylar Jeremias

Article

The 2024 surge in FDA approvals for aflibercept biosimilars reflects significant progress in offering cost-effective treatments for retinal conditions like neovascular age-related macular degeneration, although patent disputes pose challenges to their market entry and adoption.

Top 5 Most-Read Rheumatology Articles of 2024

December 30th 2024

By Skylar Jeremias

Article

The top 5 rheumatology biosimilar articles of 2024 highlight significant FDA approvals, including high-concentration adalimumab and tocilizumab biosimilars, along with evidence supporting the safety and efficacy of biosimilar-to-biosimilar switching.

The Top 5 Most-Listened to Podcasts of 2024

December 29th 2024

By Skylar Jeremias

Article

On this episode of Not So Different, we reflect on 2024 and this show in particular, taking audiences back through the most popular podcast episodes of the year.

The Top 5 Most-Read Policy Articles of 2024

December 28th 2024

By Skylar Jeremias

Article

The top biosimilar policy articles of 2024 highlight advancements that include FDA guidance to simplify biosimilar interchangeability and CMS drug price negotiations under the Inflation Reduction Act, alongside challenges posed by pharmacy benefit manager rebate practices and the need for more active stakeholder engagement.

How Vertical Integration Drives Innovation and Access in Biosimilars

December 27th 2024

By Skylar Jeremias

Article

Elie Bahou, PharmD, highlights how vertical integration in the biosimilar industry streamlines costs, improves supply reliability, accelerates market adoption, and enhances patient access, while emphasizing the value of collaboration, quality control, and value-based contracts for sustainable health care delivery.

The Top 5 Most-Read Conference Articles of 2024

December 26th 2024

By Skylar Jeremias

Article

The top 5 biosimilar conference articles in 2024 highlight significant progress in the biosimilar landscape, including strategies for market sustainability, safety of switching to biosimilars, and substantial savings through high biosimilar adoption, while also addressing ongoing challenges.

Top 5 Most-Read Regulatory Articles of 2024

December 25th 2024

By Skylar Jeremias

Article

In 2024, significant biosimilar approvals were granted by the American and European regulatory agencies, including the first interchangeability designations for biosimilars referencing ustekinumab, adalimumab, denosumab, and aflibercept, marking key regulatory milestones in improving patient access to cost-effective treatments.